Member Posts > Cardiol Therapeutics' CRD-38: A First-in-Class Therapy Addressing HF at its Root
💡 Cardiol Therapeutics (NASDAQ: CRDL) is pioneering a new approach to heart failure treatment with CRD-38, as supported by recent JACC data.
🔬 Key Features of CRD-38:
✔ Cannabidiol's Anti-Inflammatory Benefits - Protecting heart tissue from further damage.
✔ Organic Nitrates for Vasodilation - Improving oxygen flow and reducing cardiac strain.
✔ Targets Both Structural and Functional HF Deficits - Unlike conventional HF therapies.
📊 Major Preclinical Findings:
✅ Higher Ejection Fraction & Cardiac Output - Indicating stronger cardiovascular function.
✅ Reduced Fibrosis & Hypertrophy - Slowing HF progression and improving longevity.
💊 With its novel mechanism and subcutaneous administration, CRD-38 is on track to be a market disruptor in cardiovascular disease treatment.

#CardiolTherapeutics #BiotechInvesting #ClinicalTrials #PharmaStocks #CBDTherapeutics #HeartHealth #StockMarket #InvestingInBiotech #HealthcareInnovation #OrphanDrug #Myocarditis #Pericarditis #FDAApproval #GrowthStocks #MedicalBreakthroughs #CRD38 #CardiolRx